Treating shrinking of lungs
Not Applicable
- Conditions
- Health Condition 1: null- Interstitial lung disease
- Registration Number
- CTRI/2011/11/002150
- Lead Sponsor
- Institute of Pulmocare Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1. Willing to give written informed consent
2. Clinically suspected patients with ILDs with the diagnosis being substantiated through chest X-ray(PA) and HRCT chest.
Exclusion Criteria
1.History of exacerbation in past 1 month
2.History of Doxy allergy
3.Having any obvious contraindication for Doxycycline
4.Unable to meet the demand of the protocol for any reason
5.Significant abnormality in liver or renal function
6. Feature of chronic congestive cardiac failure (supported by echocardiography)
7.Known case of Idiopathic pulmonary disease with cardiovascular disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method At least no detoriation than before in subjective wellbeing of the patient and clinicoradiological and ±FVC changes.Timepoint: Between 12 weeks and 6 months after starting doxycycline with repeat spirometry.
- Secondary Outcome Measures
Name Time Method ilTimepoint: Not applicable